Table 2.

Analysis of associations between clinicopathological features and clinical outcomes of patients in the breast cancer TMA cohort

Clinicopathological features	Univariate analysis			Multivariate analysis
	HR	95% CI	P value	HR	95% CI	P value
Univariate and multivariate analyses of overall survival in breast cancer patients (n=160)
Age (>50 vs <50)	1.120	0.719-1.439	0.692
Her-2 status (Negative vs positive)	0.953	0.498-1.042	0.549
PR status (Negative vs positive)	1.503	0.621-2.482	0.732
ER status (Negative vs positive)	1.388	0.939-2.181	0.529
TNBC status (Negative vs positive)	1.063	0.729-1.875	0.495
Tumor size (>20 mm vs <20 mm)	1.249	1.029-2.054	0.260
Involved lymph node (Negative vs positive)	2.160	1.584-4.827	0.028	2.307	1.784-2.981	0.024
Differentiation grade (Well & Moderate vs Poor)	2.279	1.651-3.742	0.014	1.625	1.244-2.129	0.079
TNM stage (I & II vs III & IV)	2.679	1.951-4.841	0.000	2.532	1.986-3.821	0.002
CBX2 expression level	2.104	1.751-3.926	0.003	1.909	1.604-3.921	0.021
Univariate and multivariate analyses of relapse-free survival in breast cancer patients (n=160)
Age (>50 vs <50)	1.232	0.778-2.212	0.761
Her-2 status (Negative vs positive)	1.146	0.942-1.567	0.659
PR status (Negative vs positive)	1.728	0.821-3.011	0.842
ER status (Negative vs positive)	1.607	0.939-2.905	0.651
TNBC status (Negative vs positive)	1.163	0.910-1.754	0.545
Tumor size (>20 mm vs <20 mm)	1.327	0.729-2.154	0.286
Involved lymph node (Negative vs positive)	2.592	1.781-4.211	0.034	2.730	2.112-3.908	0.025
Differentiation grade (Well & Moderate vs Poor)	2.734	1.957-4.609	0.017	1.472	1.104-2.894	0.129
TNM stage (I & II vs III & IV)	3.214	2.011-4.942	0.000	3.021	2.809-4.391	0.006
CBX2 expression level	2.524	1.902-3.947	0.004	2.919	2.201-3.783	0.021